Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
June 04, 2019 08:00 ET
|
Emerald Bioscience, Inc.
Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald...
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
April 01, 2019 07:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 25, 2019 08:00 ET
|
Emerald Bioscience, Inc.
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
March 18, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
March 12, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
March 04, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum
January 23, 2019 07:30 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Nemus Bioscience to Present at BIO Investor Forum
October 15, 2018 08:30 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares
October 08, 2018 08:00 ET
|
Nemus Bioscience, Inc.
Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
NEMUS Bioscience to Present at The MicroCap Conference
September 26, 2018 08:00 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...